You Position: Home > Paper
Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor: Fc fusion protein: a multicentre, randomized, double blind trial
( views:573, downloads:194 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF DERMATOLOGY
- Issue:
- 11
- DOI:
- 10.3760/j.issn:0412-4030.2007.11.001
- Key Word:
- 银屑病;临床对照试验;甲氨蝶呤;重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
Abstract： 目的 评价注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(rhTNFR:Fc,商品名益赛普)治疗中、重度寻常性银屑病的临床疗效和安全性.方法 采用多中心、随机、双盲双模拟、阳性药物平行对照的临床试验.4个研究中心共144例中、重度寻常性银屑病患者,随机分为试验组和对照组,试验组皮下注射rhTNFR:Fc 50 mg/周,同时口服空白模拟甲氨蝶呤7.5 mg/周;对照组口服甲氨蝶呤7.5 mg/周,同时皮下注射空白模拟rhTNFR:Fc 50 mg/周,疗程12周.结果 124例患者完成了试验,治疗12周后,试验组PAS150、PASI75、PASI90的比例分别为86.11%,76.39%,52.78%,对照组分别为63.89%,44.44%,22.22%,两组间差异有统计学意义(P＜0.01).医生对病情的整体评分、皮肤病生活质量指数和患者10 cm视觉模拟评分试验组改善优于对照组(P＜0.05);试验组达到痊愈和几乎达到痊愈的比例显著高于对照组(P＜0.05).不良反应主要有白细胞或中性粒细胞下降、感染、肝功能异常、注射局部水肿、瘙痒等,发生率试验组为26.39%,对照组为29.17%,两组差异无统计学意义(P＞0.05),未见严重不良反应.结论 rhTNFR:Fc比甲氨蝶呤起效快,治愈率高,且毒性反应小.
- [1]Susan J, Lee,Parekha, Yedla,Arthur, Kavanaugh.Secondary immune deficiencies associated with biological therapeutics.[J].2003,3(5).
- [2]Deborah P M, Symmons,Alan J, Silman.Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.[J].2004,50(6).
- [3]Ostor AJ,Kuek A,Hazleman BL.Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.[J].2007,83(978).
- [4]Oliver Martinez V,Sanchez Carazo JL,Mahiques Santos L.Safety of etanercept in psoriasis: a critical review.[J].2006,29(8).
- [5]Zitnik R,Wang A,Leonardi CL,etc.Etanercept as monotherapy in patients with psoriasis.[J].2003,349(21).
- [6]N, Woolacott,N, Hawkins,A, Mason,etc.Etanercept and efalizumab for the treatment of psoriasis: a systematic review.[J].2006,10(46).